<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122627</url>
  </required_header>
  <id_info>
    <org_study_id>5.1.13.033</org_study_id>
    <nct_id>NCT02122627</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Patients With COPD</brief_title>
  <acronym>PRECOVID</acronym>
  <official_title>Prevention of Exacerbations in Patients With COPD Through Vitamin D Supplementation: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D has an immunomodulatory role. the aim of the present study is to assess the effect
      of vitamin D supplementation on exacerbation rate of COPD patient with a vitamin D
      deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Although vitamin D is well known for its function in calcium homeostasis and bone
      mineralisation, several studies have shown immunomodulatory effects of vitamin D. Vitamin D
      deficiency is a common problem in patients with COPD..

      Objective: To assess the effect of vitamin D supplementation on exacerbation rate in patients
      with COPD and a vitamin D deficiency.

      Study design: Randomized, multi-center, double-blind, placebo-controlled intervention study.

      Study population: 240 patients aged 40 years and older with COPD and a vitamin D deficiency
      (25-hydroxyvitamin D concentration(25OHD)&lt;50 nmol/l) with a COPD exacerbation. An
      exacerbation is defined as sustained worsening of respiratory symptoms during 48 hours and
      requiring oral corticosteroid, antibiotic or combination treatment that was initiated by a
      physician. Respiratory symptoms include at least one of the Anthonisen criteria (increased
      dyspnoea, sputum volume or purulence). Patients with a severe vitamin D deficiency (25OHD&lt;15
      nmol/l), known osteoporosis and/or use of vitamin D supplementation &gt; 400 IU per day will be
      excluded.

      Intervention: Participants will be randomly allocated to receive vitamin D3 16800 IU or
      placebo orally once a week during 1 year.

      Main study parameters/endpoints: The primary endpoint is exacerbation rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exacerbation rate</measure>
    <time_frame>1 year</time_frame>
    <description>Definition of an exacerbation is according to the Anthonisen criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first and second exacerbation</measure>
    <time_frame>1 year</time_frame>
    <description>Time to first and second exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalisation</measure>
    <time_frame>1 year</time_frame>
    <description>Time to first hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>1 year</time_frame>
    <description>Forced Expiratory Volume in 1 sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IC</measure>
    <time_frame>1 year</time_frame>
    <description>Inspiratory capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>1 year</time_frame>
    <description>Forced expiratory volume in 1 sec/ forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FRC</measure>
    <time_frame>1 year</time_frame>
    <description>Functional residual capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV</measure>
    <time_frame>1 year</time_frame>
    <description>Residual volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLC</measure>
    <time_frame>1 year</time_frame>
    <description>Total lung capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIP</measure>
    <time_frame>1 year</time_frame>
    <description>Maximal inspiratory pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEP</measure>
    <time_frame>1 year</time_frame>
    <description>Maximal expiratory pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SMWT</measure>
    <time_frame>1 year</time_frame>
    <description>Six-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chair stand test</measure>
    <time_frame>1 year</time_frame>
    <description>Chair stand test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-meter walking test</measure>
    <time_frame>1 year</time_frame>
    <description>3-meter walking test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tandem stand test</measure>
    <time_frame>1 year</time_frame>
    <description>Tandem stand test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score physical function tests</measure>
    <time_frame>1 year</time_frame>
    <description>The sum score of the physical function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand grip strength</measure>
    <time_frame>1 year</time_frame>
    <description>Hand grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SGRQ)</measure>
    <time_frame>1 year</time_frame>
    <description>QoL by the St George respiratory questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF12)</measure>
    <time_frame>1 year</time_frame>
    <description>QoL by the 12 item short form survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety (HADS)</measure>
    <time_frame>1 year</time_frame>
    <description>Anxiety by the hospital anxiety and depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression (CESD)</measure>
    <time_frame>1 year</time_frame>
    <description>Depression by the center for epidemiologic studies depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (CCQ)</measure>
    <time_frame>1 year</time_frame>
    <description>QoL by the Clinical COPD Questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of antimicrobial peptides and pro-inflammatory mediators in nasal secretions</measure>
    <time_frame>1 year</time_frame>
    <description>AMPs in nasal secretions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ex-vivo cytokine production capacity of peripheral blood mononuclear cells and immunophenotyping</measure>
    <time_frame>1 year</time_frame>
    <description>cytokine production capacity by PBMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Typing of bacteria and viruses in nasal secretions</measure>
    <time_frame>1 year</time_frame>
    <description>Typing of bacteria and viruses in nasal secretions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of corticosteroids</measure>
    <time_frame>1 year</time_frame>
    <description>Use of corticosteroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antibiotics</measure>
    <time_frame>1 year</time_frame>
    <description>Use of antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity (SQUASH)</measure>
    <time_frame>1 year</time_frame>
    <description>physical activity by short questionnaire to assess health-enhancing physical activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colecalciferol 16.800 IU per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Colecalciferol 16.800 IU per week</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Colecalciferol, cholecalciferol, vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  aged above 40 years

          -  GOLD stages II-IV and diagnosis COPD confirmed by a medical doctor.

          -  minimum of 10 packyears of smoking

          -  vitamin D deficiency (a serum 25-hydroxyvitamin D lower than 50 nmol/l)

          -  ability to comply with all study requirements

        Exclusion Criteria:

          -  pregnant or lactating women, or subjects who intend to become pregnant within the
             study period

          -  self-reported history of hypercalciemia or nephrolithiasis

          -  self-reported presence of sarcoidosis

          -  severe vitamin D deficiency (serum 25-hydroxyvitamin D lower than 15 nmol/l)

          -  life expectation of less than 6 months on the basis of concurrent disease

          -  interfering malignant diseases.

          -  diagnosed osteoporosis

          -  diagnosed asthma

          -  diagnosed chronic kidney disease stage 4 or higher (estimated glomerular filtration
             rate ≤ 29 ml/min/1,73 m2)

          -  serious mental impairment i.e. preventing to understand the study protocol or comply
             with the study aim; potentially unreliable patients and those judged by the
             investigator to be unsuitable for the study

          -  use of maintenance dose oral corticosteroids

          -  use of multivitamin supplement or vitamin D supplement which contains more than 400 IU
             per day

          -  current participation in a clinical rehabilitation programme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin den Heijer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renate de Jongh, MD, PhD</last_name>
    <phone>+31204440530</phone>
    <email>rt.dejongh@vumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Slats, PhD, MD</last_name>
      <email>a.m.slats@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André van der Ven, Prof</last_name>
      <email>andre.vanderven@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rafiq R, Aleva FE, Schrumpf JA, Heijdra YF, Taube C, Daniels JM, Lips P, Bet PM, Hiemstra PS, van der Ven AJ, den Heijer M, de Jongh RT. Prevention of exacerbations in patients with COPD and vitamin D deficiency through vitamin D supplementation (PRECOVID): a study protocol. BMC Pulm Med. 2015 Sep 23;15:106. doi: 10.1186/s12890-015-0101-4.</citation>
    <PMID>26399451</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2014</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Renate T de Jongh</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Vitamin D, COPD, immunomodulation, pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

